This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

This study has been completed.
Sun Yat-sen University
Information provided by:
Jiangsu HengRui Medicine Co., Ltd. Identifier:
First received: December 29, 2010
Last updated: February 9, 2012
Last verified: February 2012
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival compared with placebo in patients with advanced non-squamous and non-small cell lung cancer who failed two lines of chemotherapy.

Condition Intervention Phase
Non-Small-Cell Lung Cancer Drug: apatinib Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase II Study of Apatinib as Third Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Jiangsu HengRui Medicine Co., Ltd.:

Primary Outcome Measures:
  • Progression free survival [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • Overall Survival safety [ Time Frame: 8 weeks ]
  • DCR(Disease control rate) [ Time Frame: 8 weeks ]
  • ORR(objective response rate) [ Time Frame: 8 weeks ]
  • QoL(quality of life) [ Time Frame: 8 weeks ]
  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 8 weeks ]

Enrollment: 136
Study Start Date: March 2010
Study Completion Date: September 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Apatinib
Apatinib 750 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Drug: apatinib
Apatinib 750 mg p.o. once daily
Placebo Comparator: Placebo
Placebo qd p.o., and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Drug: placebo
placebo p.o. once daily


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ≥ 18 and ≤ 70 years of age
  • Histologically or cytologic confirmed advanced non-squamous and non-small cell lung cancer.
  • At least one measurable lesion which has not received radiotherapy (larger than 10 mm in diameter by spiral CT scan)
  • Have failed for 2 lines of chemotherapy including EGFR-TKI.
  • ECOG performance scale 0 - 1.
  • Life expectancy of more than 3 months.
  • Duration from the last therapy is more than 6 weeks for nitroso or mitomycin
  • More than 4 weeks after operation or radiotherapy
  • More than 4 weeks for cytotoxic agents or tyrosine kinase inhibitors inhibitors
  • Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/L, platelets ≥ 80×10^9/L, neutrophils ≥ 1.5×10^9/L, total bilirubin within 1.25×the upper limit of normal(ULN), and serum transaminase≤2.5×the ULN (If liver metastases, serum transaminase≤5×the ULN), serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥ 50ml/min,
  • signed and dated informed consent.Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.

Exclusion Criteria:

  • Squamous cell carcinoma (including adenosquamous carcinoma, undifferentiated carcinoma); small cell lung cancer (including small cell and non-small cell mixed lung cancer)
  • Pregnant or breastfeeding women
  • Intercurrence with one of the following: hypertension, coronary artery disease, arrhythmia and heart failure
  • Any factors that influence the usage of oral administration
  • PT, APTT, TT, Fbg abnormal, Receiving the therapy of thrombolysis or anticoagulation.
  • Within 4 weeks before the first use of drugs, occurs pulmonary hemorrhage (≥ CTCAE class 2) or other parts' hemorrhage (≥ CTCAE class 3).
  • Long-term untreated wounds or fractures.
  • Within 6 months before the first treatment occurs artery / venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism, etc.
  • Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogues; If the prothrombin time international normalized ratio (INR) ≤ 1.5, with the purpose of prevention, the use of small doses of warfarin (1mg orally, once daily) or low-dose aspirin (between 80mg to 100mg daily) is allowed.
  • Abuse of alcohol or drugs
  • Less than 4 weeks from the last clinical trial
  • Treatment with VEGFR, PDGFR, sSRC-TKI before.
  • History of any second malignancies within 3 years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01270386

China, Guangdong
Department of Medical Oncology, Cancer Center, Sun Yet-sen University
Guangzhou, Guangdong, China, 510060
Sponsors and Collaborators
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University
Principal Investigator: Li Zhang, Dr Sun Yat-sen University
  More Information

Responsible Party: Li Zhang, Department of Medical Oncology, Cancer Center, Sun Yet Sen University Identifier: NCT01270386     History of Changes
Other Study ID Numbers: HENGRUI 20101219
Study First Received: December 29, 2010
Last Updated: February 9, 2012

Keywords provided by Jiangsu HengRui Medicine Co., Ltd.:
phase II

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms processed this record on August 21, 2017